Sonoma Pharmaceuticals (SNOA)

Executive Summary

Sonoma Pharmaceuticals (NASDAQ: SNOA) is a global healthcare company developing and commercializing patented, shelf-stable hypochlorous acid (HOCl) solutions under its Microcyn® Technology platform. With over 20 years of experience and regulatory approvals in more than 50 countries, the company offers a range of prescription (Rx) and over-the-counter (OTC) products for wound care, dermatology, nasal/eye care, and surface disinfection. Despite its established commercial presence, Sonoma remains a small-cap company with a market valuation of approximately $4.4 million and limited liquid resources, which heightens the importance of its pipeline progress and any potential partnerships. The company's pipeline includes two Phase 1 trials for SBT777101: one in rheumatoid arthritis (expected completion in early 2026) and another in hidradenitis suppurativa (active, completion due November 2026). A prior safety trial for SBT115301 has been completed. Upcoming data from the rheumatoid arthritis study could serve as a near-term catalyst, while the hidradenitis suppurativa trial represents a later-stage opportunity. Given the early-stage nature of the pipeline and the company's low valuation, Sonoma presents a speculative investment thesis hinging on successful clinical readouts and potential commercial expansion of its Microcyn platform.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data readout for SBT777101 in rheumatoid arthritis30% success
• Q4 2026Completion of Phase 1 trial for SBT777101 in hidradenitis suppurativa25% success
• TBDPotential new product approval or distribution agreement for Microcyn platform in a major market20% success